# What the ASA found in peptide adverts Canonical: https://europeanpeptideshop.com/blog/research-peptides-uk-asa-advertising-report/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page The Advertising Standards Authority (ASA) rated 43% of the research peptide ads it assessed as high compliance risk, according to its Pulse Report dated 1 October 2026. Aesthetics Journal covered the findings on 2 November. ## How did the ASA study research peptide ads? It captured four weeks of paid ads on Meta, Google, TikTok and website display, found 309,000 healthcare ads and picked seven topics for a closer look. The research peptide group held 1,240 ads. In the rated sample 0% were low risk, 57% medium and 43% high. The ASA says the work was "not intended to make formal compliance determinations", so these are risk ratings, not rulings. ## What did it say about "research use only"? The ASA says unauthorised research peptides intended for research rather than consumer use. Many ads looked like laboratory supply on the surface. Others implied consumer use through small order quantities, WhatsApp ordering, discounts, home delivery and discreet shipping. "Research use only" wording could conflict with the surrounding presentation and purchasing process. ## What should UK readers take from it? Judge a supplier by its whole presentation, not its disclaimer. Batch-specific [COAs](https://europeanpeptideshop.com/blog/how-to-read-peptide-coa/) and plain laboratory language count for more than a footer. The ASA also flagged coded terms such as "chili peppers" in ads. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [ASA Pulse Report, 1 October 2026](https://www.asa.org.uk/resource/pulse-report-health-claims-in-online-ads.html) - [Aesthetics Journal, 2 November 2026](https://aestheticsjournal.com/news/asa-scrutiny-grows-over-peptide-and-wellness-claims/) ## More articles Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026 Research news · 3 min read ## [BPC-157: UK and US regulatory context](https://europeanpeptideshop.com/blog/is-bpc-157-legal-in-the-uk/) The October 2026 US peptide policy is not UK authorisation. Read the MHRA classification framework and why research-use wording cannot settle a product's. 8 November 2026